Skip to content

Clinical Characterization and Outcome of Anti-IgLON5 Disease

Identification, Clinical Characterization, and Prognosis of Anti-IgLON5 Disease

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06131346
Acronym
ICP-IGLON5
Enrollment
50
Registered
2023-11-14
Start date
2023-02-23
Completion date
2023-12-31
Last updated
2023-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anti-IgLON5 Disease

Keywords

Anti-IgLON5 disease, autoimmune encephalitis, neural antibodies

Brief summary

Anti-IgLON5 disease is a neurological disorder associated with antibodies to IgLON5, a neuronal cell adhesion protein of unknown function. Most patients develop a combination of significant sleep disturbances (non-rapid eye movement (NREM) and rapid eye movement parasomnias with obstructive sleep apnoea), bulbar dysfunction (dysarthria, dysphagia, vocal cord paralysis or episodes of respiratory failure) and gait instability. Early autopsy studies showed deposits of phosphorylated tau protein mainly in neurons of the brainstem tegmentum, suggesting a primary neurodegenerative disease. However, the results of subsequent studies have provided increasing support for an immune-mediated pathogenesis. First, there is a strong association with the human leukocyte antigen (HLA) haplotype DRB1\*10:01-DQB1\*05 : 01, which is present in \ 60% of patients (compared to 2% in the normal population); secondly, recent autopsy studies have shown the absence of abnormal tau deposits; and thirdly, in live neurons in culture, IgLON5 antibodies cause irreversible loss of surface IgLON5 clusters and cytoskeletal changes such as dystrophic neurites and axonal bulges. Together, these studies suggest that antibody-mediated disruption of IgLON5 function leads to neurofilament and cytoskeletal alterations that can potentially result in tau accumulation. Over the last two years, an increase in diagnoses of anti-IgLON5 disease has been observed in the French Reference centre of Autoimmune Encephalitis. This could be related to a better knowledge of the disease, or to other yet unknown factors. Clinical characterisation of these patients is essential to understand the underlying reasons for the increase in diagnoses and to improve knowledge of this disease. Furthermore, the response of these patients to immunosuppressive drugs and the long-term prognosis remain unknown.

Interventions

OTHEREvaluation of clinical and paraclinical data.

Retrospective data collection from available medical files of patient.

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Patients \> 18 ans * Anti-IgLON5 antibody positivity

Exclusion criteria

\- Lack of clinical data

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of IGLON5 disorderAt baselinePrevalence of : * Sleeping disorders * Respiratory dosorders * Cognitive disorders * Abnormal movements

Countries

France

Contacts

Primary ContactJerome Honnorat, professor
jerome.honnorat@chu-lyon.fr33472357806
Backup ContactMarine Villard
marine.villard@chu-lyon.fr0427855460

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026